Clinical outcomes, toxic effect, and immune microenvironment changes of drug-eluting bead bronchial arterial chemoembolisation/bronchial arterial chemoembolization combined with immunotherapy in treating elderly patients with non–small cell lung cancer

This publication has 26 references indexed in Scilit:

• Immunotherapy or Chemoimmunotherapy in Older Adults With Advanced Non–Small Cell Lung Cancer
  JAMA Oncology, 2024
• Efficacy and Safety of Drug-Eluting Beads Bronchial Arterial Chemoembolization in Treating Patients with Lung Cancer Who Were Complicated with Hemoptysis
  Cancer Biotherapy and Radiopharmaceuticals, 2023
• Severe immune-related adverse events of immune checkpoint inhibitors for advanced non-small cell lung cancer: a network meta-analysis of randomized clinical trials
  Cancer Immunology, Immunotherapy, 2022
• Clinical Effectiveness and Safety of Anti-PD-(L)1 Therapy Among Older Adults With Advanced Non-Small Cell Lung Cancer
  Clinical Lung Cancer, 2022
• Sintilimab plus Bronchial Arterial Infusion Chemotherapy/Drug-Eluting Embolic Chemoembolization for Advanced Non–Small Cell Lung Cancer: A Preliminary Study of 10 Patients
  Journal of Vascular and Interventional Radiology, 2021
• Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors Among Patients Aged 80 Years or Older With Cancer
  JAMA Oncology, 2021
• Predictive value of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in non-small cell lung cancer patients treated with immune checkpoint inhibitors: A meta-analysis
  International Immunopharmacology, 2020
• Systemic immune‐inflammation index, neutrophil‐to‐lymphocyte ratio, platelet‐to‐lymphocyte ratio can predict clinical outcomes in patients with metastatic non‐small‐cell lung cancer treated with nivolumab
  Journal of Clinical Laboratory Analysis, 2019
• Cancer Immunotherapies: Are They as Effective in the Elderly?
  Drugs & Aging, 2017
• Cancer-related inflammation
  Nature, 2008